Novo Nordisk A/S Investors Notified of Class Action Securities Lawsuit

Novo Nordisk A/S (NYSE: NVO) investors who were affected by alleged securities fraud between May 7, 2025 and July 28, 2025, have been notified of a class action lawsuit. The complaint alleges that the company provided false and misleading statements about its growth potential, specifically regarding the impact of the personalization exception to the compounded GLP-1 exclusion. Following an announcement by Novo on July 29, 2025, lowering its sales and profit outlook, the company's stock price plummeted by 21.83% in a single day.

Key Takeaways:

• The lawsuit covers Novo investors who suffered losses between May 7, 2025, and July 28, 2025.
• The complaint alleges that Novo provided false and misleading statements about its growth potential, specifically regarding the compounded GLP-1 exclusion.
• The company's stock price declined by 21.83% on July 29, 2025, following an announcement of lower sales and profit outlook.
• Novo attributed the guide down to lowered growth expectations for the second half of 2025 due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition."
• Levi & Korsinsky, LLP is representing the investors and has secured hundreds of millions of dollars for aggrieved shareholders in complex securities litigation.

Statistics:

• The lawsuit covers a time frame of 62 days (May 7, 2025, to July 28, 2025).
• The stock price decline on July 29, 2025, was 21.83% from $69.00 to $53.94 per share.
• Levi & Korsinsky, LLP has secured over $100 million for shareholders in previous cases.

Sources:

• "Novo Nordisk A/S Investors", Levi & Korsinsky, LLP (2025)
• "Levi & Korsinsky, LLP Notifies Investors in Novo Nordisk A/S", PRNewswire (2025)
• "Levi & Korsinsky, LLP", Levi & Korsinsky, LLP (2025)